Maastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer. CPC634 is a new drug […]
EuroTides
/in News /by Alex JonesNovember 6 EuroTides Amsterdam, The Netherlands
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline
/in News /by Alex JonesMaastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). […]
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
/in News /by Alex JonesMaastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer. CPC634 is a new drug […]
ESMO 36th Annual Congress 2018
/in News /by Alex JonesOctober 19-23 ESMO 36th Annual Congress 2018 Munich, Germany
BioJapan
/in News /by Alex JonesOctober 10-12 BioJapan Yokohama, Japan
Clinam 11
/in News /by Alex JonesSeptember 2-5 Clinam 11 Basel, Switzerland
Gordon Research Conference
/in News /by Alex JonesAugust 12-18 Gordon Research Conference Mount Snow, USA
The Koch institute – MIT nanomedicines
/0 Comments/in News /by Alex JonesJune 15 The Koch institute – MIT nanomedicines Boston/Cambridge, USA
Bio International Convention
/in News /by Alex JonesJune 4-7 Bio International Convention Boston, USA
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials
/in News /by Alex JonesMaastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming […]